Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats

被引:0
|
作者
Swarbrick, Michael M. M. [3 ,4 ,5 ]
Cox, Chad L. L.
Graham, James L. L.
Knudsen, Lotte B. B.
Stanhope, Kimber
Raun, Kirsten
Havel, Peter J. J. [1 ,2 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Nutr, One Shields Ave, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, One Shields Ave, Davis, CA 95616 USA
[3] Univ Sydney, ANZAC Res Inst, Bone Res Program, Concord, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Concord Clin Sch, Sydney, Australia
[5] Novo Nordisk AS, Malov, Denmark
基金
美国国家卫生研究院;
关键词
diabetes mellitus; food intake; growth hormone; insulin; liraglutide; obesity; TYPE-2; DIABETES-MELLITUS; INSULIN-RESISTANCE; PEPTIDE-1; ANALOG; SKELETAL-MUSCLE; GLUCOSE-TOLERANCE; OBESITY; MODEL; ADIPONECTIN; SENSITIVITY; WEIGHT;
D O I
10.1002/edm2.392
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP-1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and delay the onset of type 2 diabetes mellitus (T2DM). In UCD-T2DM rats, a model of polygenic obesity and insulin resistance, we have previously reported that daily liraglutide administration delayed diabetes onset by > 4 months. Growth hormone (GH) may exert anti-diabetic effects, including increasing beta-cell mass and insulin secretion, while disrupting GH signalling in mice reduces both the size and number of pancreatic islets. We therefore hypothesized that GH supplementation would augment liraglutide's anti-diabetic effects.MethodsMale UCD-T2DM rats were treated daily with GH (0.3 mg/kg) and/or liraglutide (0.2 mg/kg) from 2 months of age. Control (vehicle) and food-restricted (with food intake matched to liraglutide-treated rats) groups were also studied. The effects of treatment on diabetes onset and weight gain were assessed, as well as measures of glucose tolerance, lipids and islet morphology.ResultsLiraglutide treatment significantly reduced food intake and body weight and improved glucose tolerance and insulin sensitivity, relative to controls. After 4.5 months, none of the liraglutide-treated rats had developed T2DM (overall p = .019). Liraglutide-treated rats also displayed lower fasting triglyceride (TG) concentrations and lower hepatic TG content, compared to control rats. Islet morphology was improved in liraglutide-treated rats, with significantly increased pancreatic insulin content (p < .05 vs. controls). Although GH treatment tended to increase body weight (and gastrocnemius muscle weight), there were no obvious effects on diabetes onset or other diabetes-related outcomes.ConclusionGH supplementation did not augment the anti-diabetic effects of liraglutide.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Cardiac NF-κB Acetylation Increases While Nrf2-Related Gene Expression and Mitochondrial Activity Are Impaired during the Progression of Diabetes in UCD-T2DM Rats
    Thorwald, Max A.
    Godoy-Lugo, Jose A.
    Rodriguez, Ruben
    Stanhope, Kimber L.
    Graham, James L.
    Havel, Peter J.
    Forman, Henry Jay
    Ortiz, Rudy M.
    ANTIOXIDANTS, 2022, 11 (05)
  • [32] Chronic Administration of the Glucagon-Like Peptide 1(GLP-1) Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Plasma Triglycerides in a Novel Rat Model of Type 2 Diabetes, the UCD-T2DM Rat
    Havel, Peter J.
    Cummings, Bethany P.
    Graham, James L.
    Stanhope, Kimber L.
    Griffen, Steven C.
    Knudsen, Lotte B.
    Nilsson, Cecilia
    Raun, Kirsten
    DIABETES, 2009, 58 : A366 - A366
  • [33] UPLC-Q-TOF/MS based fecal metabolomics reveals the potential anti-diabetic effect of Xiexin Decoction on T2DM rats
    Zhang, Zhi-Miao
    Chen, Meng-Jun
    Zou, Jun-Feng
    Jiang, Shu
    Shang, Er-Xin
    Qian, Da-Wei
    Duan, Jin-Ao
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2021, 1173
  • [34] Hybrid drug combination: Anti-diabetic treatment of type 2 diabetic Wistar rats with combination of ellagic acid and pioglitazone
    Nankar, Rakesh P.
    Doble, Mukesh
    PHYTOMEDICINE, 2017, 37 : 4 - 9
  • [35] Impaired Mesenteric Arterial Function of Male UC Davis Type 2 Diabetes Mellitus (UCD-T2DM) Rats: Possible Involvement of Small Conductance Calcium-activated Potassium Channels (SKca)
    Razan, Md Rahatullah
    Akther, Farjana
    Wang, Der Yu
    Shaligram, Sonali
    Graham, James L.
    Stanhope, Kimber L.
    Havel, Peter J.
    Rahimian, Roshanak
    FASEB JOURNAL, 2018, 32 (01):
  • [36] Anti-Diabetic Effects of a Coptis chinensis Containing New Traditional Chinese Medicine Formula in Type 2 Diabetic Rats
    Zhen, Zhong
    Chang, Bai
    Li, Min
    Lian, Feng-Mei
    Chen, Liang
    Dong, Liu
    Wang, Jia
    Yu, Bo
    Liu, Wen-Ke
    Li, Xiu-Yang
    Qin, Pei-Jie
    Zhang, Jing-Hua
    Tong, Xiao-Lin
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2011, 39 (01): : 53 - 63
  • [37] Anti-Diabetic and Anti-Hyperlipidemic Effects of 2-[(Trimethylsilyl)-Oxy]-, Trimethylsilyl Ester Isolated from Pericampylus glaucus in Diabetic Rats
    Kifayatullah, Muhammad
    Mahmood, Fawad
    Shah, Nisar Z.
    Khan, Muhammad A.
    Ali, Nasir
    Khayam, Sahibzada M. U.
    Amin, Fazli
    LATIN AMERICAN JOURNAL OF PHARMACY, 2018, 37 (01): : 22 - 28
  • [38] Relationship between metabolomics of T2DM patients and the anti-diabetic effects of Phellodendri Chinensis Cortex-Anemarrhenae Rhizoma herb pair in mice
    Yu, Jia-Lin
    Zhang, Zhen-Yang
    Liu, Sheng-Ping
    Long, Hong-Ping
    Wang, Ting-Ting
    Huang, Feng-Qing
    Guo, Jia
    Xu, Wei-Long
    Li, Fei
    JOURNAL OF ETHNOPHARMACOLOGY, 2025, 339
  • [39] Patterns of Up-Titration in Type 2 Diabetes (T2DM) Patients Taking Oral Anti-Diabetic Drugs (OADs)
    Krishnarajah, Girishanthy
    Bhosle, Monali
    Chapman, Richard
    DIABETES, 2009, 58 : A318 - A319
  • [40] Common Channel Length in Bypass Surgery Does Not Impact T2DM in Diabetic Zucker Rats
    Laessle, Claudia
    Michelmichel, Sven
    Marjanovic, Goran
    Kuesters, Simon
    Seifert, Gabriel
    Hopt, Ulrich T.
    Fink, Jodok Matthias
    OBESITY SURGERY, 2017, 27 (08) : 2090 - 2098